Brentuximab vedotin vs physician's choice in CTCL patients from the Phase 3 ALCANZA study: Analysis of outcomes by CD30 expression Meeting Abstract
| Authors: | Kim, Y. H.; Prince, H. M.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Bechter, O.; Wang, Y.; Palanca-Wessels, M. C.; Wood, K. W.; Li, M.; Liu, Y.; Lin, H.; Little, M.; Danaee, H.; Trepicchio, W.; Dummer, R. |
| Abstract Title: | Brentuximab vedotin vs physician's choice in CTCL patients from the Phase 3 ALCANZA study: Analysis of outcomes by CD30 expression |
| Meeting Title: | 14th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Jun 14-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2017-06-07 |
| Start Page: | 77 |
| End Page: | 78 |
| Language: | English |
| ACCESSION: | 123459764 |
| DOI: | 10.1002/hon.2437_65 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 66 -- Accession Number: 123459764 -- Entry Date: In Process -- Revision Date: 20170608 -- Publication Type: Article -- Supplement Title: Jun2017 Supplement -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
